LetterBenefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study
References (5)
- et al.
Alopecia areata update: part II. Treatment
J Am Acad Dermatol
(2010) Current treatment of alopecia areata
J Investig Dermatol Symp Proc
(2013)
Cited by (41)
Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology
2020, Anais Brasileiros de DermatologiaCitation Excerpt :Classically, the concentration of 2.5–10 mg/mL of triamcinolone is used for the scalp and 2.5–5 mg/mL for the face and other body areas.3,25 A pilot study showed that lower concentrations, such as 2.5 mg/mL, were as effective as higher concentrations and with a lower risk of atrophy.26 An alternative option to TH for the intralesional treatment of AA is betamethasone (betamethasone dipropionate 5 mg/mL + disodium phosphate betamethasone 2 mg/mL).18
Treatments for alopecia areata: a network meta-analysis
2023, Cochrane Database of Systematic ReviewsAlopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: Treatment
2023, Przeglad DermatologicznyAlopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
2023, Clinical, Cosmetic and Investigational DermatologyHair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point
2022, Clinical Reviews in Allergy and Immunology
Funding sources: None.
Disclosure: Dr Shapiro has received honoraria for serving as a consultant and speaker for Merck, Johnson & Johnson, and Applied Biology. Drs Shapiro and McElwee are also the founders and shareholders of Replicel Life Sciences Inc. Drs Chu, Al Jasser, Alharbi, and Abahussein have no conflicts of interest to declare.